Marvel Biosciences Corp. says it has signed a letter of intent with Novatech for a Phase 1 clinical trial involving its candidate MB-204. The company also provides a corporate update alongside the announcement.

The company describes Marvel as a drug discovery firm focused on autism spectrum disorder (ASD) and related neurodevelopmental disorders. In connection with the Phase 1 work, it characterizes Novatech as an Asia-Pacific full-service contract research organization (CRO), serving small to mid-sized biotech and pharmaceutical companies. Both outlets present the announcement primarily as an early, non-binding agreement through a letter of intent, rather than a finalized trial contract or regulatory authorization.

While the two reports emphasize the same core development—an LOI for a Phase 1 trial of MB-204 and related corporate information—they mainly differ in framing. One outlet highlights the corporate update and the company’s announcement format, while the other underscores Novatech’s market role and CRO positioning.